망막분지정맥폐쇄에 합병된 황반부종에서 유리체강내 베바시주맙 주입술이 삶의 질에 미치는 영향

• 영문명: Impact of Intravitreal Bevacizumab Injection on Life Quality in Patients with Branch Retinal Vein Occlusion
• 발행기관: 대한안과학회
• 저자명: 김지욱 최경식 이미리 이성진,Jee Wook Kim, MD, Kyung Seek Choi, MD, PhD, Mi Ri Rhee, MD, Sung Jin Lee, MD, PhD
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume53,number10, 1465~1471쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2012.10.15

영문 초록

Purpose: To evaluate the impact of intravitreal bevacizumab injection on visual function and vision-related quality of life (VR-QOL) in patients with branch retinal vein occlusion (BRVO) using the Korean version of the National Eye Institute Visual Function Questionnaire 25 (K-NEI-VFQ-25). Methods: This study included 32 normal control subjects and 32 patients with BRVO. The Korean version of NEI-VFQ-25 was answered by the patients with BRVO before and 3 months after intravitreal bevacizumab injection, as well as by normal control subjects. Clinical data were collected, including central macular thickness (CMT), total macular volume (TMV) (using time-domain optical coherence tomography [OCT]), and best corrected visual acuity (BCVA). Results: Visual acuity, CMT, and TMV significantly improved 3 months after intravitreal bevacizumab injections. No bevacizumab- related systemic or ocular adverse effects following intravitreal drug injections were observed. Significant improvement in the VFQ-25 composite score was observed in patients with BRVO. Subscale scores, including general vision, near activities, distance activities, social functioning, mental health, role difficulties, dependency, and peripheral vision, improved after injection. However, subscale scores regarding general health, ocular pain, driving, and color vision did not improve significantly. Conclusions: Intravitreal bevacizumab injection appears to be an effective treatment for visual function, as well as VR-QOL in macular edema secondary to BRVO. However, improvement of driving function and color vision appears to require a longer recovery time than visual function. J Korean Ophthalmol Soc 2012;53(10):1465-1471

키워드

Bevacizumab, BRVO, VR-QOL